News & Events

Guangzhou, July 14, 2026 — Guangzhou Lupeng Pharmaceutical Co., Ltd. has reached another important R&D milestone: the first patient has been successfully enrolled in the Phase Ib/II clinical study (CTR20261866, study ID LP-10822) evaluating rocbrutinib in combination with lacutoclax for the treatment of B-cell malignancies.

GUANGZHOU, China, July 14, 2026 — Guangzhou Lupeng Pharmaceutical achieved another major milestone in its R&D pipeline with the successful enrollment of the first patient in the pivotal Phase II clinical study (CTR20261956; study number LP-10821) of its highly selective BCL-2 inhibitor, lacutoclax（LP-108）, for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL).

The 31st Annual Congress of the European Hematology Association (EHA) was held in Stockholm, Sweden, started on June 11, 2026. This year's congress brought together top experts and scholars in the global hematology field. For the first time， Lupeng Pharmaceutical reported the single-agent efficacy data of rocbrutinib for the treatment of relapsed or refractory Primary Central Nervous System lymphoma (R/R PCNSL). Lupeng Pharmaceutical also updated the efficacy and safety data of rocbrutinib after prolonged follow-up in the ROCK-1 study.

Guangzhou, China, June 4, 2026 — Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development code: LP-168) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) who have received at least two prior systemic therapies, including BTK inhibitors.

Head-to-Head Study Highlights Rocbrutinib as the World’s First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations